SCHEMBL744269

SCHEMBL744269

CC(C)(C)OC(=O)N[C@H](C(=O)O)C(Cc1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.57
ACE P12821 1/20 0.56
CTSS P25774 3/20 0.55
CTSK P43235 2/20 0.55
CTSL P07711 1/20 0.55
CTSB P07858 1/20 0.55
APP P05067 3/20 0.54
PPARA Q07869 2/20 0.51
PPARG P37231 1/20 0.51
KMT2A Q03164 3/20 0.50
KLK5 Q9Y337 2/20 0.50
MEN1 O00255 1/20 0.48
AKT1 P31749 1/20 0.48
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7346811 1.00 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL7316279 1.00 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL9439279 1.00 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL7407045 1.00 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL7309827 0.91 ATM (0.54) ATMACECTSSCTSKCTSL
SCHEMBL9737911 0.91 ATM (0.54) ATMACECTSSCTSKCTSL
SCHEMBL1150914 0.91 KLK5 (0.58) ATMACECTSSCTSKCTSL
SCHEMBL23699313 0.86 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL23699315 0.86 ATM (0.57) ATMACECTSSCTSKCTSL
SCHEMBL23699391 0.86 ATM (0.57) ATMACECTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0274423-A2 Method for the production of crystalline amino-protected-beta-benzyl-L-aspartic acid ORTHO PHARMACEUTICAL CORPORATION (US) 1988-07-13 EP claimed
US-4713480-A Method for the production of crystalline amino-protected-beta-benzyl-L-aspartic acid ORTHO PHARMACEUTICAL CORPORATION (US) 1987-12-15 US claimed
EP-2397488-B1 DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS FEDERAL STATE BUDGETARY INSTITUTION RES ZAKUSOV INSTITUTE OF PHARMACOLOGY (RU) 2019-03-27 EP disclosed
US-9683014-B2 Dipeptide mimetics of NGF and BDNF neurotrophins UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN (RU) 2017-06-20 US disclosed
EP-2431403-B1 POLYMER CONJUGATE OF BIOACTIVE SUBSTANCE HAVING HYDROXY GROUP NIPPON KAYAKU KK (JP) 2016-09-28 EP disclosed
US-20150111828-A1 DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII (RU) 2015-04-23 US disclosed
US-8808749-B2 Polymer conjugate of bioactive substance having hydroxy group NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-08-19 US disclosed
CN-102421827-B Polymer conjugate of bioactive substance having hydroxy group NIPPON KAYAKU KK 2014-07-30 CN disclosed
US-20120116051-A1 Polymer Conjugate Of Bioactive Substance Having Hydroxy Group NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2012-05-10 US disclosed
CN-102421827-A Polymer conjugate of bioactive substance having hydroxy group NIPPON KAYAKU KK 2012-04-18 CN disclosed
EP-2431403-A1 POLYMER CONJUGATE OF BIOACTIVE SUBSTANCE HAVING HYDROXY GROUP Nippon Kayaku Kabushiki Kaisha (JP) 2012-03-21 EP disclosed
EP-0136879-A2 Fatty acid derivatives and processes of producing them YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1985-04-10 EP disclosed
US-4505853-A GLANDULAR DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1985-03-19 US disclosed
US-4369137-A N-Protected pentapeptides useful as intermediates in the preparation of thymopoietin pentapeptide ORTHO PHARMACEUTICAL CORPORATION (US) 1983-01-18 US disclosed
EP-0042291-A2 Methods and compositions for preparation of H-Arg-X-Z-Y-Tyr-R ORTHO PHARMACEUTICAL CORPORATION (US) 1981-12-23 EP disclosed
US-4301045-A RESIN PEPTIDES ARMOUR PHARMACEUTICAL COMPANY (US) 1981-11-17 US disclosed
US-4298523-A OLIGOPEPTIDES OF ARGININE, LYSINE, VALINE, SARCOSINE, ASPARTIC OR GLUTAMIC ACID, AND TYROSINE ORTHO PHARMACEUTICAL CORPORATION (US) 1981-11-03 US disclosed
US-4191808-A DIPEPTIDE CONTAINING PROLINE AND A PHOTOMETRICALLY DETECTABLE NITROANILINE, PHENYLAZOANILINE OR PHENYLAZONAPHTHYLAMINE GROUP AJINOMOTO CO., INC. (JP) 1980-03-04 US disclosed
US-4161522-A OLIGOPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1979-07-17 US disclosed
US-4119620-A Novel dipeptide derivatives, salts thereof, and method of measuring enzyme activity AJINOMOTO CO., INC. (JP) 1978-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111828-A1 DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS BDNF, NTRK2, NGF ATM 3028/4885ACE 2496/4885CTSS 3014/4885
US-20120116051-A1 Polymer Conjugate Of Bioactive Substance Having Hydroxy Group CTSL, CPA3, ADCY10 ATM 3758/4885ACE 764/4885CTSS 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.